eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Source: Globenewswire
Leadership Appointment: eXoZymes Inc. has appointed Damien Perriman as Chief Commercial Officer to enhance its commercial growth, leveraging his extensive experience in biotechnology commercialization across various markets.
Innovative Biomanufacturing: The company focuses on developing AI-engineered enzymes, known as exozymes, which aim to revolutionize sustainable chemical production by overcoming limitations of traditional methods and enabling scalable biosolutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
